These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9560002)

  • 1. The design, synthesis and activity of pentapeptide pp60c-src inhibitors containing L-phosphotyrosine mimics.
    Lai JH; Marsilje TH; Choi S; Nair SA; Hangauer DG
    J Pept Res; 1998 Apr; 51(4):271-81. PubMed ID: 9560002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of efficient pentapeptide substrates for the tyrosine kinase pp60c-src.
    Nair SA; Kim MH; Warren SD; Choi S; Songyang Z; Cantley LC; Hangauer DG
    J Med Chem; 1995 Oct; 38(21):4276-83. PubMed ID: 7473555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain:phosphotyrosine mimetics exploiting multifunctional group replacement chemistry.
    Sundaramoorthi R; Kawahata N; Yang MG; Shakespeare WC; Metcalf CA; Wang Y; Merry T; Eyermann CJ; Bohacek RS; Narula S; Dalgarno DC; Sawyer TK
    Biopolymers; 2003; 71(6):717-29. PubMed ID: 14991680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic peptides incorporating 4-carboxyphenylalanine and phosphotyrosine are potent inhibitors of pp60(c-)(src).
    Wang W; Ramdas L; Sun G; Ke S; Obeyesekere NU; Budde RJ; McMurray JS
    Biochemistry; 2000 May; 39(17):5221-8. PubMed ID: 10819990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
    Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
    J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic peptide substrates of pp60c-src. Synthesis and evaluation.
    McMurray JS; Budde RJ; Dyckes DF
    Int J Pept Protein Res; 1993 Sep; 42(3):209-15. PubMed ID: 7693604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tetrapeptide tyrosine kinase inhibitors. Enantioselective synthesis of p-hydroxymethyl-L-phenylalanine, incorporation into a tetrapeptide, and subsequent elaboration into p-(R,S-hydroxyphosphonomethyl)-L-phenylalanine.
    Kim MH; Lai JH; Hangauer DG
    Int J Pept Protein Res; 1994 Nov; 44(5):457-65. PubMed ID: 7896504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide ligands of pp60(c-src) SH2 domains: a thermodynamic and structural study.
    Charifson PS; Shewchuk LM; Rocque W; Hummel CW; Jordan SR; Mohr C; Pacofsky GJ; Peel MR; Rodriguez M; Sternbach DD; Consler TG
    Biochemistry; 1997 May; 36(21):6283-93. PubMed ID: 9174343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
    Ye B; Akamatsu M; Shoelson SE; Wolf G; Giorgetti-Peraldi S; Yan X; Roller PP; Burke TR
    J Med Chem; 1995 Oct; 38(21):4270-5. PubMed ID: 7473554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
    Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
    Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
    Nam NH; Ye G; Sun G; Parang K
    J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent dipeptide inhibitors of the pp60c-src SH2 domain.
    Pacofsky GJ; Lackey K; Alligood KJ; Berman J; Charifson PS; Crosby RM; Dorsey GF; Feldman PL; Gilmer TM; Hummel CW; Jordan SR; Mohr C; Shewchuk LM; Sternbach DD; Rodriguez M
    J Med Chem; 1998 May; 41(11):1894-908. PubMed ID: 9599239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent pseudosubstrate-based peptide inhibitors for p60(c-src) protein tyrosine kinase.
    Lou Q; Leftwich ME; McKay RT; Salmon SE; Rychetsky L; Lam KS
    Cancer Res; 1997 May; 57(10):1877-81. PubMed ID: 9157979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel phosphotyrosine mimetic 4'-carboxymethyloxy-3'-phosphonophenylalanine (Cpp): exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain.
    Kawahata N; Yang MG; Luke GP; Shakespeare WC; Sundaramoorthi R; Wang Y; Johnson D; Merry T; Violette S; Guan W; Bartlett C; Smith J; Hatada M; Lu X; Dalgarno DC; Eyermann CJ; Bohacek RS; Sawyer TK
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2319-23. PubMed ID: 11527723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and characterization of novel fluorogenic substrates of coagulation factor XIII-A.
    Hardes K; Zouhir Hammamy M; Steinmetzer T
    Anal Biochem; 2013 Nov; 442(2):223-30. PubMed ID: 23933241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel nonphosphorylated pentapeptide motif displaying high affinity for Grb2-SH2 domain by the utilization of 3'-substituted tyrosine derivatives.
    Song YL; Peach ML; Roller PP; Qiu S; Wang S; Long YQ
    J Med Chem; 2006 Mar; 49(5):1585-96. PubMed ID: 16509576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and metal binding of novel Pseudo- oligopeptides containing two phosphinic acid groups.
    Ye Y; Liu M; Kao JL; Marshall GR
    Biopolymers; 2008 Jan; 89(1):72-85. PubMed ID: 17910046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographical constraints in peptide design.
    Alfaro-Lopez J; Yuan W; Phan BC; Kamath J; Lou Q; Lam KS; Hruby VJ
    J Med Chem; 1998 Jun; 41(13):2252-60. PubMed ID: 9632358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach.
    Kamath JR; Liu R; Enstrom AM; Lou Q; Lam KS
    J Pept Res; 2003 Dec; 62(6):260-8. PubMed ID: 14632929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-myristoylation of a peptide substrate for Src converts it into an apparent slow-binding bisubstrate-type inhibitor.
    Ramdas L; Obeyesekere NU; Sun G; McMurray JS; Budde RJ
    J Pept Res; 1999 May; 53(5):569-77. PubMed ID: 10424353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.